Building a better tomorrow for Kentuckians with cancer: Farish Fund gives $5 million to establish new Markey Urologic Cancer Program
The University of Kentucky Markey Cancer Center has received a $5 million gift to establish the Ambassador William Stamps Farish Program of Excellence in Urologic Cancer.
The gift, made by the William Stamps Farish Fund through the Markey Cancer Foundation, was announced at a June 1 special event held on the Markey campus. The gift will be formally accepted later in June, subject to UK Board of Trustees approval.
“At UK HealthCare, we pride ourselves on giving patients options that they can’t find anywhere else in Kentucky,” said Dr. Mark F. Newman, executive vice president for health affairs at UK HealthCare. “It’s our goal that no Kentuckian should have to leave the state for health care. Funding from generous donors like the Farish family helps us make that a reality.”
Joining Dr. Newman at the event were Dr. Stephen Strup, James F. Glenn Professor and Chairman of Urology; Sally Humphrey, Markey Cancer Foundation board chair emerita; Dr. Charles Griffith, acting dean of the UK College of Medicine; Dr. Robert DiPaola, UK provost; Dr. Mark Evers, Markey Cancer Center director; and Dr. Pamela Hull, Farish Chair in Cancer Research.
The William Stamps Farish Fund has generously provided numerous gifts to the Markey Cancer Center through the years, supporting recruitment of physicians and researchers and helping expand UK HealthCare’s cancer treatment and research programs. This most recent gift, named for William Stamps Farish III, former U.S. ambassador to the United Kingdom, provides additional investment in faculty recruitment and clinical research.
“Citizens across the Commonwealth and beyond turn to us — the University for Kentucky — for compassionate care and solutions to the most complex problems,” said UK President Eli Capilouto. “I firmly believe that this new partnership holds such great promise for this state and those we serve. Thank you to the Farish family for making that possible.”
The establishment of the Ambassador William Stamps Farish Program of Excellence in Urologic Cancer will be marked with a named space inside the new Markey Cancer Center Urologic Cancer Clinic, which is scheduled to open in 2025.
“Philanthropy is crucial for us to reach our goals, and I’m incredibly grateful for this new gift from the Farish Fund,” Dr. Evers said. “This funding will specifically help us address an all-too-common problem in our state – our high rates of prostate, kidney and bladder cancer.”
Cancer disproportionately affects Kentuckians compared with other U.S. populations. Urologic cancers account for three of the 10 most frequently diagnosed in the Commonwealth (prostate, kidney and bladder). The establishment of this new program will help Markey pursue its vision of transforming the way urologic cancers are diagnosed and treated – and drastically improving outcomes in Kentucky and beyond.
The Markey Cancer Center is one of just 71 National Cancer Institute-designated cancer centers in the U.S., but this latest gift from the William Stamps Farish Fund will aid Markey in its pursuit of NCI Comprehensive Cancer Center designation. Only 52 such centers exist in the United States, and none are within a 200-mile radius of Lexington.
NCI Comprehensive Cancer Center designation would provide Markey with exclusive access to certain clinical trials, new opportunities for collaboration with leading scientists around the world and a powerful recruitment tool to attract the best available physicians and researchers. Numerous studies show that patients treated at NCI-Designated Comprehensive Cancer Centers have better survival and recovery rates.
“We want to give Kentuckians their best chance at a long and healthy life,” said William S. Farish, a of the gift bearing his father’s name, “and this gift will provide more resources for patients, including more providers and improved access to the latest early phase clinical trials, as close to home as possible.”
This content was produced by UK HealthCare Brand Strategy.